Fiche publication
Date publication
avril 2026
Journal
Advances in therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Peyrin-Biroulet L, Seenan JP, Armuzzi A, Lazar A, Eldred A, Doan T, Polakow SB, Al Mahi N, Liu M, Nader A, Bhatnagar S, Schreiber S
Lien Pubmed
Résumé
The monoclonal antibody ravagalimab is a potent antagonist to cluster of differentiation 40 (CD40), which is elevated in inflammatory diseases such as ulcerative colitis (UC). This phase 2a, open-label trial evaluated the efficacy and safety of ravagalimab as induction and maintenance treatment in patients with moderate-to-severe UC and who had inadequate response, loss of response, or intolerance to prior therapy.
Mots clés
Anti-CD40, Biomarkers, CD40 antagonist, CD40 receptor occupancy, CD40 target engagement, Clinical remission, Clinical response, Endoscopic improvement, Immunomodulatory, Ravagalimab, Treatment of moderate-to-severe ulcerative colitis
Référence
Adv Ther. 2026 04 1;:
